FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters
Incorporating PTS and LLD status might improve selection of targeted first-line treatment in RAS-WT mCRC patients. FOLFIRI/Cet appears to be particularly beneficial for LC/non-LLD patients with mitigated benefit in patients with LC/LLD. In contrast, FOLFIRI/Bev is significantly favoured over FOLFIRI/Cet in patients with RC/non-LLD. Notably, RC/LLD patients may still benefit from anti-EGFR therapy despite right-sided primary tumor. These results are hypothesis-generating and warrant further validation.
Authors
- Lena Weiss (ORCID: https://orcid.org/0000-0002-8101-3529)
- Markus Moehler (ORCID: https://orcid.org/0000-0003-4071-8562)
- Arndt Stahler (ORCID: https://orcid.org/0000-0003-1041-0137)
- Alexander J. Ohnmacht (ORCID: https://orcid.org/0000-0002-1481-9426)
- Alexander Kiani (ORCID: https://orcid.org/0000-0002-2494-4087)
- Sebastian Stintzing (ORCID: https://orcid.org/0000-0002-3297-5801)
- Volker Heinemann (ORCID: https://orcid.org/0000-0002-1349-3321)
- Thomas Decker (ORCID: https://orcid.org/0000-0003-3814-8775)
- Julian Walter Holch (ORCID: https://orcid.org/0000-0002-4755-0179)
- Michael P. Menden (ORCID: https://orcid.org/0000-0003-0267-5792)
- Dominik Paul Modest (ORCID: https://orcid.org/0000-0002-6853-0599)
- Hartmut Link (ORCID: https://orcid.org/0000-0002-9659-0265)
- Kathrin Heinrich (ORCID: https://orcid.org/0000-0003-3580-2313)
- Christoph Kahl (ORCID: https://orcid.org/0000-0002-9370-5928)
- Tobias Heintges
- Florian Kaiser (ORCID: https://orcid.org/0000-0002-5844-1779)
- Victoria Probst (ORCID: https://orcid.org/0009-0008-8038-7351)
- Ludwig Fischer von Weikersthal (ORCID: https://orcid.org/0000-0002-9128-0807)
- Frank Kullmann
- Heinz‐Gert Höffkes
Institutions
- German Cancer Research Center (DE)
- Johannes Gutenberg University Mainz (DE)
- University of Applied Sciences Landshut (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Bayreuth Medical Center (DE)
- Helmholtz Zentrum München (DE)
- Humboldt-Universität zu Berlin (DE)
- Westpfalz Klinikum (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Ravensburg University of Cooperative Education (DE)
- German Cancer Society (DE)
- Klinikum Magdeburg (DE)
- Klinikum Weiden (DE)
- Kliniken der Stadt Köln (DE)
- Klinikum St. Marien Amberg (DE)
- Klinikum Fulda (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1016/j.ejca.2025.115388
- Citations
- 3
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Merck KGaA
- Pfizer UK